November 24, 2016 - By Marguerite Chambers
N+1 Singer maintained their “Corporate” rating on shares of Abzena Plc (LON:ABZA) in a research report revealed to clients and investors on Thursday morning.
Out of 2 analysts covering Abzena Plc (LON:ABZA), 2 rate it a “Buy”, 0 “Sell”, while 0 “Hold”. This means 100% are positive. GBX 100 is the highest target while GBX 98 is the lowest. The GBX 99 average target is 205.56% above today’s (GBX 32.4) stock price. Abzena Plc has been the topic of 9 analyst reports since September 14, 2015 according to StockzIntelligence Inc. The stock of Abzena PLC (LON:ABZA) has “Corporate” rating given on Thursday, January 7 by N+1 Singer. The company was maintained on Friday, October 21 by N+1 Singer. The firm earned “Corporate” rating on Monday, January 25 by N+1 Singer. The firm has “Buy” rating by N+1 Singer given on Monday, September 21. The firm has “Corporate” rating given on Tuesday, November 24 by N+1 Singer. The stock has “Buy” rating given by FinnCap on Friday, November 18. The stock has “Buy” rating given by N+1 Singer on Monday, September 14. N+1 Singer maintained Abzena PLC (LON:ABZA) rating on Monday, October 12. N+1 Singer has “Buy” rating and GBX 98 price target.
Abzena PLC (LON:ABZA) has declined 35.00% since April 25, 2016 and is downtrending. It has underperformed by 40.41% the S&P500.
Abzena plc is a life sciences company. The company has a market cap of 45.12 million GBP. The Firm provides technologies and complementary services to enable the development and manufacture of biopharmaceutical products. It currently has negative earnings. It has a global customer base which includes approximately 20 biopharmaceutical companies, as well as large and small biotech companies and academic groups.
More news for Abzena PLC (LON:ABZA) were recently published by: Businesswire.com, which released: “Abzena plc: Placing to Raise £20 Million and Acquisition” on November 24, 2015. Businesswire.com‘s article titled: “Abzena Plc: PacificGMP Makes Two Senior Appointments” and published on January 28, 2016 is yet another important article.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.